Gain insights into how new guidances could transform the rare disease landscape, including your drug development program.
This week's Fierce Biotech is brought to you by Premier Research. Trouble viewing? Click here. |
| |
WEBINAR | | The Future State of Orphan Drug Development | | Tuesday, February 25 @ 11 am EST | | | |
|
|
| | | | A Rare Look into New Development Guidances | | With many rare diseases still lacking treatments, regulatory agencies are stepping up with new guidances to support innovation, advance research, and improve patient outcomes. | | Learn how the latest guidances are shaping the rare disease landscape and gain tips to support compliance and efficiency in your drug development program. | | |
|
---|
| | |
| What You will learn | | | | | The impact of the latest guidances on rare clinical research |
|
| | | | Study design strategies to ensure efficiency and compliance |
|
|
---|
| | | A medic's perspective on what the changes will mean for patients and investigators |
|
| | | | Current developments and 2024 approval trends |
|
|
---|
| | |
|
| | | | | Premier Research, a clinical research, product development, and consulting company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. | | | Visit premier-research.com | | |
|
|
Want to reach 137,000+ Fierce Biotech subscribers with your own message? Contact aalcover@questex.com or call 202-824-5074.
You are currently subscribed as newsletter@newslettercollector.com. If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe. Refer to our Privacy Policy. Questex, LLC 685 3rd Avenue, 21st Floor New York, NY 10017 |